Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Register entry · Comment-period correspondents

Dr Xenia Uttridge

Comment-period correspondent, hepatology. Public-sector clinical trials unit

Document identifier
CEI-RG-163
Series
Register entry
Version
1.0
Published
15 Jan 2025
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Register entry

§1.1Register entry

Name
Dr Xenia Uttridge
Credentials
MSc (Regulatory Affairs)
Role
Comment-period correspondent, hepatology
Body
Comment-period correspondents
Affiliation
Public-sector clinical trials unit
Registered since
2025
Specialism
hepatology

§1.2Declared interests

Declared interests are published in full for every register entry. A declaration is not a disqualification, and the Institute has never given a submission or a review less weight on that ground. The materiality threshold and the recusal rules are set out in the conflicts-of-interest policy, which was settled through public consultation.

§1.3Attribution

Comment-period correspondents are listed in this register having consented at the point of submission. The Institute publishes no submission from a person who did not consent to be named.

Compound Evidence Institute · CEI-RG-163 · https://compoundevidence.com/people/dr-xenia-uttridge/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.